Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 30 vs ESIMIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Hypertension (to lower blood pressure, not for initial therapy)
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
2.3 ± 0.4 hours; prolonged in renal impairment (up to 6.5 hours in severe cases).
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Olmesartan: undergoes hepatic ester hydrolysis to active metabolite, not metabolized by CYP450 system. Amlodipine: extensively metabolized in liver via CYP3A4. Hydrochlorothiazide: not significantly metabolized.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Primarily renal (>90% as unchanged drug); biliary/fecal <10%.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
40-50% bound to albumin.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
1.5-2.0 L/kg; suggests extensive tissue distribution.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
Oral: 55-65% due to first-pass metabolism.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
e GFR 30-89 m L/min: no adjustment. e GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended.
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Not approved for pediatric use; safety and efficacy not established.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
Start at 2.5 mg once daily due to increased sensitivity and risk of adverse effects.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Discontinue as soon as possible when pregnancy is detected. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Fetal toxicity (see black box warning),Hypotension in volume-depleted patients,Monitor renal function; may increase serum creatinine and BUN,Electrolyte disturbances (hypokalemia, hyponatremia, hypercalcemia),Exacerbation of angina or acute MI (especially with rapid dose increase of amlodipine),Acute angle-closure glaucoma (with HCTZ),Systemic lupus erythematosus exacerbation (with HCTZ),Metabolic acidosis (with HCTZ),Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min)
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Hypersensitivity to any component,Anuria (due to HCTZ),Concomitant use with aliskiren in patients with diabetes
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Food may delay absorption; take on an empty stomach for best results. Avoid acidic beverages (e.g., orange juice) within 30 minutes of dosing. No significant food restrictions but a low-acid diet may help symptom control.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some retrospective studies. In the second and third trimesters, use may be associated with reduced uterine blood flow and fetal tachycardia; avoid near term due to risk of neonatal irritability. Overall, use only if clearly needed and after first trimester.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio ~2.5-3.5). It may reduce milk production, especially with chronic use. The relative infant dose is estimated at 2-5% of maternal weight-adjusted dose. Caution is advised; monitor infant for irritability, sleep disturbances, and feeding problems.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
No standard dose adjustments are recommended, but due to increased renal clearance in pregnancy, therapeutic effects may be reduced. Use the lowest effective dose for the shortest duration. Avoid sustained-release formulations in pregnancy due to unpredictable absorption.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
ESIMIL (esomeprazole) is a proton pump inhibitor (PPI) used for acid-related disorders. Onset of action is rapid, but maximal acid suppression occurs after 5-7 days. Best taken before breakfast for optimal effect. Avoid co-administration with clopidogrel due to reduced efficacy. Monitor magnesium levels with prolonged use, especially in patients taking diuretics or digoxin. Consider calcium and vitamin D supplementation to mitigate osteoporosis risk.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
Take this medication 30-60 minutes before a meal, preferably breakfast.,Swallow capsules whole; do not crush or chew.,Do not take with other acid reducers unless directed.,Report symptoms of severe diarrhea, bone pain, or muscle cramps.,Avoid alcohol and spicy foods that may worsen symptoms.,Long-term use may increase risk of fractures; ensure adequate calcium intake.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 30 vs ESIMIL, answered by our medical review team.
ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. ESIMIL is a Unknown that works by Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 30 and ESIMIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. The standard adult dose of ESIMIL is: 5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 30 and ESIMIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. ESIMIL is classified as Category C. Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.